A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients

Kidney International, Supplement

Volumn 63, Issue 84, 2003, Pages

  Pecoits Filho, Roberto ^a   Stenvinkel, Peter ^b   Marchlewska, Alicia ^b   Heimburger, Olof ^b   Bárány, Peter ^b   Hoff, Catherine M ^b   Holmes, Clifford J ^b   Suliman, Mohamed ^b   Lindholm, Bengt ^b   Schalling, Martin ^b   Nordfors, Louise ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

End stage renal disease; Genetic polymorphism; Myeloperoxidase; Oxidative stress

Indexed keywords

CELL DNA; FREE RADICAL; INTERLEUKIN 6; MYELOPEROXIDASE; PENTOSIDINE; SERUM ALBUMIN; ARGININE; DRUG DERIVATIVE; LYSINE; PEROXIDASE;

ADULT; ALLELE; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; CONTROLLED STUDY; DIALYSIS; DISEASE MARKER; DNA DETERMINATION; DNA SEQUENCE; ENZYME ACTIVITY; GENE ACTIVITY; GENE EXPRESSION; GENETIC EPIDEMIOLOGY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFLAMMATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALNUTRITION; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROLOGY; SEROPREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ARTERIOSCLEROSIS; ARTICLE; BLOOD; CHLAMYDIASIS; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; FEMALE; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; RISK FACTOR;

ARGININE; ARTERIOSCLEROSIS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DIABETIC NEPHROPATHIES; FEMALE; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; LYSINE; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 0037406516     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.63.s84.32.x     Document Type: Conference Paper

References (19)

1. HIMMELFARB J, STENVINKEL P, IKIZLER A, et al: The elephant of uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62(5):1524-1538, 2002
2. HOY A, LEININGER-MULLER B, KUTTER D, et al: Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 40:2-8, 2002
3. PIEDRAFITA FJ, MOLANDER RB, VANSANT G, et al: An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271:14412-14420, 1996
4. NORDFORS L, JANSSON M, SANDBERG G, et al: Large-scale genotyping of single nucleotide polymorphisms by pyrosequencing and validation against the 5′nuclease (Taqman) assay. Hum Mutat 19:395-401, 2002
5. STENVINKEL P: Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 19:53-61, 2001
6. PODREZ EA, ABU-SOUD HM, HAZEN SL: Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 28:1717-1725, 2000
7. REYNOLDS WF, RHEES J, MACIEJEWSKI D, et al: Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 155:31-41, 1999
8. LONDON SJ, LEHMAN TA, TAYLOR JA: Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 57:5001-5003, 1997
9. NIKPOOR B, TURECKI G, FOURNIER C, et al: A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 142:336-339, 2001
10. REYNOLDS WF, CHANG E, DOUER D, et al: An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 90:2730-2737, 1997
11. BUFFON A, BIASUCCI LM, LIUZZO G, et al: Widespread coronary inflammation in unstable angina. N Engl J Med 347:5-12, 2002
12. DAUGHERTY A, DUNN JL, RATERI DL, et al: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94:437-444, 1994
13. HAZEN SL, HEINECKE JW: 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 99:2075-2081, 1997
14. EISERICH JP, BALDUS S, BRENNAN ML, et al: Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296:2391-2394, 2002
15. HIMMELFARB J, MCMENAMIN ME, LOSETO G, et al: Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 31:1163-1169, 2001
16. ANDERSON MM, REQUENA JR, CROWLEY JR, et al: The myeloperoxidase system of human phagocytes generates nepsilon-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products as sites of inflammation. J Clin Invest 104:103-113, 1999
17. MIYATA T, WADA Y, CAI Z, et al: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51:1170-1181, 1997
18. MIYATA T, MAEDA K, KUROKAWA K, et al: Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 12:255-258, 1997
19. KUTTER D, DEVAQUET P, VANDERSTOCKEN G, et al: Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit? Acta Haematol 104:10-15, 2000